



# BAISHIDENG PUBLISHING GROUP INC

7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 33005

**Title:** Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C

**Reviewer's code:** 03538158

**Reviewer's country:** Japan

**Science editor:** Yuan Qi

**Date sent for review:** 2017-02-04

**Date reviewed:** 2017-02-05

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

### COMMENTS TO AUTHORS

1. Authors should mention that establishment of HBV infection and its replication space is limited by the antiviral effects of type I interferon in the chronically HCV-infected liver (Wieland SF, et al. J Virol 2014;88:5184-8). 2. Without DAAs, reappearance of serum hepatitis B viral DNA in patients with hepatitis B surface antigen seroclearance are occasionally observed (Nakamura M, et al. Hepatology. 2015 Oct;62(4):1329. doi: 10.1002/hep.27693.). Authors should distinguish between HBV reactivation and HBV DNA reappearance. In Table 1, authors should describe the ALT levels and rewrite the text. 3. In page 5, "...Recent studies have reported that treatment with direct-acting antivirals (DAAs) for hepatitis C virus (HCV) treatment may cause HBV reactivation in patients with HCV/HBV coinfection [15-21]...."



# BAISHIDENG PUBLISHING GROUP INC

7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 33005

**Title:** Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C

**Reviewer's code:** 03537672

**Reviewer's country:** Japan

**Science editor:** Yuan Qi

**Date sent for review:** 2017-02-04

**Date reviewed:** 2017-02-08

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

### COMMENTS TO AUTHORS

This reviewer have one point requestd to authors. 1. Please provide the recommended treatment algorithm for those with the coinfection of HBV and HCV in a figure.

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 33005

**Title:** Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C

**Reviewer's code:** 03662544

**Reviewer's country:** Taiwan

**Science editor:** Yuan Qi

**Date sent for review:** 2017-02-04

**Date reviewed:** 2017-02-11

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

### COMMENTS TO AUTHORS

Overall, this article comprehensive review the issues of DAA treatment in HBV/HCV co-infected patients and highlight the risk of HBV reactivation among this cohort. It is well written and with organized structure. The following opinion were provided for authors' review. 1. Discussion section: 2nd paragraph, line 6: "In particular, patients with chronic HBV who developed HCV have shown decreased HBV replication " --- It will be better to re-write this sentence for better understandable. 2. EASL guidelines suggest that if HBV DNA is detectable in HBs antigen-negative, anti-HBc antibody-positive patients ("occult" hepatitis B), concurrent HBV nucleoside /nucleotide analogue therapy is indicated. But AASLD guidelines suggest the patients with low or undetectable HBV DNA levels should be monitored at regular intervals (usually not more frequently than every 4 weeks) and initiate HBV therapy when DNA levels meet treatment criteria. --- It would be better to provide the author's expert view-point to comment about this difference between two official guidelines. a little more pros and cons



## BAISHIDENG PUBLISHING GROUP INC

7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

<http://www.wjgnet.com>

---

discussion about treat immediately or treat until DNA levels meet treatment criteria may help the readers. 3. The Chinese author Wang's observation study find that when clinical hepatitis occurred in HCV/occult HBV co-infected group, it is not related to HBV reactivation, but rather related to intake of herb or binge of alcohol. It would be helpful to put it in discussion section to provide differential diagnostic thinking alternatives.

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 33005

**Title:** Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C

**Reviewer's code:** 03662609

**Reviewer's country:** United States

**Science editor:** Yuan Qi

**Date sent for review:** 2017-02-04

**Date reviewed:** 2017-02-19

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input checked="" type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input checked="" type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

### COMMENTS TO AUTHORS

While the scientific content of this editorial paper is sound and of interest, it was extremely distracting to review because of the excessive amount of English language and English grammar errors. It is not the role of a reviewer to correct language errors of the extent found in this submission. There are English language/grammar errors throughout the paper but they are most numerous in the section "Reactivation of hepatitis B in HCV infected patients". I have stated some errors below in example but there are many more errors besides these: 1) it is standard that generic drug names start with a small letter e.g tenofovir not Tenofovir 2)DAA versus DAAs - one is singular, the other is plural and singular should be used as appropriate throughout the article 3) data is plural - it should be 'these data' not 'this data' 4) standard procedure when writing journal articles is to explain an abbreviation in brackets the first time it is used - this should be done for all HBV serology abbreviations used in the article e.g HBsAg (hepatitis B surface antigen). Before submitting to an English language journal the



## BAISHIDENG PUBLISHING GROUP INC

7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

<http://www.wjgnet.com>

---

authors should have had the submission reviewed by someone who is sufficiently proficient in written English, engaging a professional editing service for a language check if necessary. The level of English language proficiency with which the article is currently written makes it unacceptable for publication in an English language journal.